Moderna (MRNA) reports a director or officer change
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Moderna disclosed in a November 13, 2026 Form 8-K that Chief Legal Officer Shannon Thyme Klinger will retire, remaining employed until March 31, 2027, while transitioning duties and resigning all officer positions by that date or an earlier date designated by the company. Klinger will keep her current salary and benefits and continue vesting equity until the retirement date, and she remains eligible for a 2026 bonus based on her target multiplied by the board-determined corporate performance factor. She will receive severance of $1,628,300 paid biweekly over twelve months, plus COBRA premiums through September 30, 2028, subject to early termination if she gains coverage elsewhere. The agreement also ties additional payouts to litigation outcomes: $2,500,000 if Moderna prevails against Arbutus Biopharma and Genevant Sciences, and up to $5,500,000 depending on results in proceedings involving Pfizer, BioNTech and related parties. The filing includes standard releases of claims, and investors will watch who Moderna names as successor and how the flagged litigation concludes.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.
Named in this story
Shannon Thyme Klinger, Moderna (MRNA)
A linked name opens that asset's sentiment page.